Epidemiology and Real-World Evidence, AstraZeneca, Oncology, Gaithersburg, MD, U.S.A.
Health Economics and Outcomes Research, Optum, Eden Prairie, MN, U.S.A.;
Anticancer Res. 2021 Feb;41(2):927-936. doi: 10.21873/anticanres.14846.
BACKGROUND/AIM: Limited published real-world data describe adverse events (AEs) among patients treated for mantle-cell lymphoma (MCL). The aim of this retrospective study was to describe treatment patterns, AEs, and associated healthcare costs.
Patients had two or more claims coded for MCL diagnosis, the first claim date (07/01/2012-05/31/2017) was the index date. Patients with pre-index MCL diagnosis or systemic treatment, or hematopoietic stem cell transplantation were excluded. Cohorts by regimen were followed for up to three lines of therapy.
Patients (n=395; median age 72 years; 31% female) were observed over a total of 576 lines of therapy, the most common being bendamustine plus rituximab; rituximab monotherapy; R-CHOP; and ibrutinib. The most frequent AEs were hypertension (40.5%), anemia (37.7%), and infection (36.1%). However, hepatotoxicity ($19,645), stroke ($18,893), and renal failure ($9,037) were associated with the highest medical costs per patient per month.
Among patients receiving common systemic treatments for MCL, AEs occurred frequently; some imposed substantial inpatient care costs.
背景/目的：有限的已发表的真实世界数据描述了接受套细胞淋巴瘤 (MCL) 治疗的患者的不良事件 (AE)。本回顾性研究的目的是描述治疗模式、AE 及相关医疗保健成本。
患者有两个或更多编码为 MCL 诊断的索赔，首次索赔日期（2012 年 7 月 1 日至 2017 年 5 月 31 日）为索引日期。排除有预索引 MCL 诊断或系统治疗或造血干细胞移植的患者。按方案对队列进行了最多三条治疗线的随访。
共观察到 395 例患者（中位年龄 72 岁，31%为女性）接受了 576 条治疗线，最常见的是苯达莫司汀联合利妥昔单抗、利妥昔单抗单药、R-CHOP 和伊布替尼。最常见的 AE 是高血压 (40.5%)、贫血 (37.7%)和感染 (36.1%)。然而，肝毒性（$19645）、中风（$18893）和肾衰竭（$9037）与每位患者每月的最高医疗费用相关。
在接受 MCL 常见系统治疗的患者中，AE 频繁发生；某些 AE 导致大量住院治疗费用。
